Actelion to buy Ceptaris, as long as FDA OKs Valchlor
This article was originally published in Scrip
Executive Summary
The Swiss company Actelion is to buy the privately owned Ceptaris, but only if the US FDA approves Ceptaris' Valchlor, which would become the first authorized topical mechlorethamine gel for treating early stage mycosis fungoides-type cutaneous T cell lymphoma (CTCL).
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.